Evaluating LP-10 in Subjects With OLP
a study on Oral Lichen Planus
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Kamal Al-Eryani, DDS (ucsf)
Description
Summary
This is a multicenter, dose-ranging study including adult male and female subjects (>= 18 years old) with symptomatic Oral Lichen Planus (OLP). A total of approximately 24 subjects will be enrolled at approximately eight (8) study sites in the United States. This study will evaluate the safety, tolerability and efficacy of LP-10 at 0.25 mg, 0.5 mg and 1.0 mg of tacrolimus.The study consists of screening, treatment and follow-up phases. The treatment phase includes 10 mL LP-10 oral rinse for 3 minutes twice a day for 4 weeks. The follow-up phase includes one post-treatment visit 2 weeks after the last oral LP-10 dose.
Official Title
A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability, and Efficacy of LP-10 in Subjects With Symptomatic Oral Lichen Planus
Keywords
Oral Lichen Planus, OLP, Lichen Planus, Tacrolimus, LP-10 (Liposomal Tacrolimus)
Eligibility
You can join if…
Open to people ages 18 years and up
- Provide written informed consent
- Male or female ≥ 18 years of age
- Oral biopsy performed within the last 10 years before the Screening Visit demonstrating OLP and/or oral lichenoid mucositis in the absence of cancer or dysplasia
- Moderate OLP based on an OLP Investigator Global Assessment (IGA) score of ≥ 3
- OLP Pain and Sensitivity Numerical Rating Scale (NRS) score of ≥ 3
- Patients taking prescription oral steroid or rinse treatment(s) at the time of the Screening Visit agree to stop treatment for the duration of the trial and to undergo a 4-week washout period
- Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the self-administered questionnaires
- Willing to avoid live vaccines while enrolled in the trial
- Patients of child-bearing potential must have a negative pregnancy test and agree to undergo pregnancy testing at each study visit. (unless patient has undergone a bilateral tubal ligation or hysterectomy and/or is post-menopausal as defined by the absence of menses for at least 12 months)
- Patients of child-bearing potential and male participants with a female partner of child-bearing potential, agree to use a reliable method of contraception (condoms and/or oral contraceptives) for the duration of the trial and for 10 days thereafter
You CAN'T join if...
- Hyperkalemia
- Chronic kidney disease
- Long QT syndrome
- History of oral cavity or oropharyngeal cancers
- Active cancer
- Uncontrolled hypertension (i.e., > 145 mm/Hg systolic or > 95 mmHg diastolic)
- Patients who failed tacrolimus treatment for OLP in the past
- Patient who is currently or has previously participated in another oral cavity therapeutic or device study within 3 months of screening and has not returned to baseline
- History of oral cavity infection (bacterial, viral or fungal) within 3 months prior to screening
- Pregnant or lactating
- Active bleeding peptic ulcer disease
- Known allergy to liposomes and/or egg yolk and/or tacrolimus
- Evidence of renal impairment (creatinine > 2 × the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > 3 × the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases per investigator's judgment
- Patients currently taking magnesium and aluminum-hydroxide antacids or metoclopramide
- Patients currently taking aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, and protease inhibitors
- The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study
Locations
- UCSF School of Dentistry
accepting new patients
San Francisco California 94143 United States - Center for Dermatology
accepting new patients
Fremont California 94538 United States
Lead Scientist at University of California Health
- Kamal Al-Eryani, DDS (ucsf)
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Lipella Pharmaceuticals, Inc.
- ID
- NCT06233591
- Phase
- Phase 2 Oral Lichen Planus Research Study
- Study Type
- Interventional
- Participants
- Expecting 24 study participants
- Last Updated